Table 1

Baseline characteristics according to pre-study DMD treatment (intent-to-treat population; n = 119)

Number (%) of patients

Age, years

Duration of MS, years

EDSS score*

PASAT score

HADS Anxiety score

HADS Depression score


Pre-study DMD

Median (range); 95% confidence interval


im IFN β-1a

75 (63.0)

39

5

2

42.5

7

5

(19-58)

(0-22)

(0-5.5)

(5-60)

(0-20)

(0-20)

35.6, 39.9

4.9, 7.3

1.9, 2.4

40.0, 45.3

6.9, 9.2

4.9, 7.0

IFN β-1b

26 (21.8)

37

3.5

1.5

48

7

3.5

(20-52)

(0-22)

(0-6)

(24-59)

(0-13)

(0-15)

34.1, 42.4

3.1, 8.6

1.3, 2.4

42.6, 50.8

5.0, 7.8

3.5, 7.1

Glatiramer acetate

15 (12.6)

41

4

1.5

35

7

3

(18-55)

(1-8)

(0-4.5)

(18-52)

(0-14)

(0-12)

31.7, 44.5

2.7, 5.3

1.3, 2.9

30.5, 41.9

3.8, 9.0

2.3, 7.0

sc IFN β-1a

3 (2.5)

35

6

3

46

4

6

(22-43)

(6-11)

(2-4)

(25-51)

(4-10)

(2-6)

7.0, 59.6

0.5, 14.8

0.5, 5.5

6.4, 74.9

-2.6, 14.6

-1.1, 10.4


*Range: 0 (no disability) to 10 (severe disability resulting in death)

Range: 0 to 60 (higher scores indicate better cognitive function)

Range: 0 to 21 (higher scores indicate more severe symptoms)

n = 72

DMD disease-modifying drug, EDSS Expanded Disability Status Scale, HADS Hospital Anxiety and Depression Scale, IFN interferon, im intramuscular, MS multiple sclerosis, PASAT Paced Auditory Serial Addition Task, sc subcutaneous

Lugaresi et al. BMC Neurology 2012 12:7   doi:10.1186/1471-2377-12-7

Open Data